Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc.

CTKB

NASDAQHealthcareMedical - Devices

Previous close

$4.81

+$0.15 · +3.22%

Aug 21, 4:00 PM ET

Pre-market

$4.6909

−$0.1191 · -2.48%

Aug 24, 4:18 AM ET

CTKB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

50

Neutral

Sentiment

62

Bullish

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Wenbin Jiang
Listed since
Jul 23, 2021
Employees
682

Market position

Day range

Current $4.81

52-week range

Current $4.81

Open
$4.64
Previous close
$4.66
Volume
820.26K
0.69× average
Average volume
1.2M
Average daily volume
Market cap
621.18M USD
Beta
1.17
Market reference 1
50-day average
$4.4326
+8.51% above average
200-day average
$4.6113
+4.31% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-7.72×
P/B (TTM)
1.93×
P/S (TTM)
3.01×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
53.23%
Operating margin
-21.60%
Net margin
-38.98%

Financial health

Debt / equity
0.08×

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-143.66%
11 comparable reports
Latest EPS result
-0.05
Estimate -0.09 · Beat by 46.43%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.11-0.05-0.22-0.38Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.07, estimate 0.05, surprise +40.00%, Beat. Q2 2025, reported May 8, 2025: actual -0.09, estimate -0.04, surprise -125.00%, Miss. Q3 2025, reported Aug 6, 2025: actual -0.04, estimate -0.02, surprise -100.00%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.01, estimate -0.03, surprise +66.67%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.34, estimate -0.02, surprise -1600.00%, Miss. Q2 2026, reported May 7, 2026: actual -0.12, estimate -0.08, surprise -50.00%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.05, estimate -0.093, surprise +46.43%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates64.63M56.07M47.52M38.97MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 57.48M USD, estimate 59.38M USD, surprise -3.21%, Miss. Q2 2025, reported May 8, 2025: actual 41.46M USD, estimate 42.66M USD, surprise -2.83%, Miss. Q3 2025, reported Aug 6, 2025: actual 45.6M USD, estimate 46.34M USD, surprise -1.60%, Miss. Q4 2025, reported Nov 5, 2025: actual 52.29M USD, estimate 51.21M USD, surprise +2.12%, Beat. Q1 2026, reported Feb 26, 2026: actual 62.14M USD, estimate 57.15M USD, surprise +8.73%, Beat. Q2 2026, reported May 7, 2026: actual 44.14M USD, estimate 44.23M USD, surprise -0.22%, Miss. Q3 2026, reported Aug 5, 2026: actual 48.14M USD, estimate 47.31M USD, surprise +1.76%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 52.95M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.88

1.46% upside
Past 12 months12-month forecastHigh $5.00Average $4.88Low $4.75

Rating distribution

5 ratings
Strong buy00%
Buy360%
Hold120%
Sell120%
Strong sell00%

CTKB peers

ETFs holding CTKB

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CTKB

research.disclaimer